Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities

ACS Chemical Neuroscience

Volumn 4, Issue 9, 2013, Pages 1256-1266

  Healy, Jason R ^a   Bezawada, Padmavani ^b   Shim, Jihyun ^b   Jones, Jace W ^b   Kane, Maureen A ^b   MacKerell, Alexander D ^b   Coop, Andrew ^b   Matsumoto, Rae R ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antinociception; conformationally sampled pharmacophore; delta antagonist; mu agonist; opioid receptor; tolerance

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4A,9 DIHYDROXY 7A (HYDROXYMETHYL) 3 METHYL 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO [3,2 E]ISOQUINOLIN 7(7AH); BUPRENORPHINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; DIPRENORPHINE; ETORPHINE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OXYMORPHINDOLE; THEBAINE; UMB 425; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; HOT PLATE TEST; IN VIVO STUDY; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF; RECEPTOR BINDING; SAMPLING; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; CHO CELLS; COMPUTER SIMULATION; CRICETULUS; DRUG EVALUATION, PRECLINICAL; DRUG TOLERANCE; HUMANS; MALE; MICE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MORPHINE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTIVE PAIN; PAIN MEASUREMENT; PROTEIN BINDING; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; THEBAINE; TRANSFECTION;

EID: 84884408705     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn4000428     Document Type: Article

References (54)

1. Cherny, N. J., Chang, V., Frager, G., Ingham, J. M., Tiseo, P. J., Popp, B., Portenoy, R. K., and Foley, K. M. (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration Cancer 76, 1283-1293
2. Walder, B., Schafer, M., Henzi, I., and Tramer, M. R. (2001) Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review Acta Anaesthesiol. Scand. 45, 795-804
3. Caudill-Slosberg, M. A., Schwartz, L. M., and Woloshin, S. (2004) Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000 Pain 109, 514-519
4. Benyamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., Glaser, S. E., and Vallejo, R. (2008) Opioid complications and side effects Pain Physician 11, S105-120
5. Manchikanti, K. N., Manchikanti, L., Damron, K. S., Pampati, V., and Fellows, B. (2008) Increasing deaths from opioid analgesics in the United States: an evaluation in an interventional pain management practice J. Opioid Manage. 4, 271-283
6. Waldhoer, M., Bartlett, S. E., and Whistler, J. L. (2004) Opioid receptors Annu. Rev. Biochem. 73, 953-990
7. Stein, C., Schafer, M., and Machelska, H. (2003) Attacking pain at its source: new perspectives on opioids Nat. Med. 9, 1003-1008
8. Wang, J. B., Johnson, P. S., Persico, A. M., Hawkins, A. L., Griffin, C. A., and Uhl, G. R. (1994) Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment FEBS Lett. 338, 217-222
9. Evans, C. J., Keith, D. E., Jr., Morrison, H., Magendzo, K., and Edwards, R. H. (1992) Cloning of a delta opioid receptor by functional expression Science 258, 1952-1955
10. Mansson, E., Bare, L., and Yang, D. (1994) Isolation of a human kappa opioid receptor cDNA from placenta Biochem. Biophys. Res. Commun. 202, 1431-1437
11. Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dolle, P., Tzavara, E., Hanoune, J., Roques, B. P., and Kieffer, B. L. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene Nature 383, 819-823
12. Horan, P., Tallarida, R. J., Haaseth, R. C., Matsunaga, T. O., Hruby, V. J., and Porreca, F. (1992) Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity Life Sci. 50, 1535-1541
13. Abdelhamid, E. E., Sultana, M., Portoghese, P. S., and Takemori, A. E. (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice J. Pharmacol. Exp. Ther. 258, 299-303
14. Schiller, P. W., Fundytus, M. E., Merovitz, L., Weltrowska, G., Nguyen, T. M., Lemieux, C., Chung, N. N., and Coderre, T. J. (1999) The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats J. Med. Chem. 42, 3520-3526
15. Portoghese, P. S. (1989) Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists Trends Pharmacol. Sci. 10, 230-235
16. Daniels, D. J., Lenard, N. R., Etienne, C. L., Law, P. Y., Roerig, S. C., and Portoghese, P. S. (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series Proc. Natl. Acad. Sci. U.S.A. 102, 19208-19213
17. George, S. R., Fan, T., Xie, Z., Tse, R., Tam, V., Varghese, G., and O'Dowd, B. F. (2000) Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties J. Biol. Chem. 275, 26128-26135
18. Morphy, R. and Rankovic, Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48, 6523-6543
19. Schiller, P. W. (2010) Bi- or multifunctional opioid peptide drugs Life Sci. 86, 598-603
20. Ananthan, S., Khare, N. K., Saini, S. K., Seitz, L. E., Bartlett, J. L., Davis, P., Dersch, C. M., Porreca, F., Rothman, R. B., and Bilsky, E. J. (2004) Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone] J. Med. Chem. 47, 1400-1412
21. Shim, J., Coop, A., and MacKerell, A. D., Jr. (2011) Consensus 3D model of mu-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore J. Phys. Chem. B 115, 7487-7496
22. Bernard, D., Coop, A., and MacKerell, A. D., Jr. (2007) Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity J. Med. Chem. 50, 1799-1809
23. Bernard, D., Coop, A., and MacKerell, A. D., Jr. (2003) 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists J. Am. Chem. Soc. 125, 3101-3107
24. Lutfy, K. and Cowan, A. (2004) Buprenorphine: a unique drug with complex pharmacology Curr. Neuropharmacol. 2, 395-402
25. Gates, M., Boden, R. M., and Sundararaman, P. (1989) Derivatives of the thebaine anion. 2. 5-Methylmorphine, 5-methylcodeine, 5-methylheroin and some related compounds J. Org. Chem. 54, 972-974
26. Woudenberg, R. H., Lie, T.-S., and Maat, L. (1993) Chemistry of opium alkaloids. 38. Synthesis of rigid morphinans doubly bridged at ring C J. Org. Chem. 58, 6139-6142
27. Lotfy, H. R., Schultz, A. G., and Metwally, M. A. (2003) Synthesis of 5-methoxymethyl, 5-(2-methoxyethyl), and 5-allyl thebaine, codeinone, and morphinone derivatives Russ. J. Org. Chem. 39, 1256-1260
28. Rice, K. C. (1977) A rapid, high-yield conversion of codeine to morphine J. Med. Chem. 20, 164-165
29. Clark, M. J., Emmerson, P. J., Mansour, A., Akil, H., Woods, J. H., Portoghese, P. S., Remmers, A. E., and Medzihradsky, F. (1997) Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor J. Pharmacol. Exp. Ther. 283, 501-510
30. Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., and Kobilka, B. K. (2012) Structure of the delta-opioid receptor bound to naltrindole Nature 485, 400-404
31. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 485, 321-326
32. Toll, L., Berzetei-Gurske, I. P., Polgar, W. E., Brandt, S. R., Adapa, I. D., Rodriguez, L., Schwartz, R. W., Haggart, D., O'Brien, A., White, A., Kennedy, J. M., Craymer, K., Farrington, L., and Auh, J. S. (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications NIDA Res. Monogr. 178, 440-466
33. King, M. A., Su, W., Nielan, C. L., Chang, A. H., Schutz, J., Schmidhammer, H., and Pasternak, G. W. (2003) 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile Eur. J. Pharmacol. 459, 203-209
34. Wells, J. L., Bartlett, J. L., Ananthan, S., and Bilsky, E. J. (2001) In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence J. Pharmacol. Exp. Ther. 297, 597-605
35. Ananthan, S., Saini, S. K., Dersch, C. M., Xu, H., McGlinchey, N., Giuvelis, D., Bilsky, E. J., and Rothman, R. B. (2012) 14-Alkoxy- and 14-acyloxypyridomorphinans: mu agonist/delta antagonist opioid analgesics with diminished tolerance and dependence side effects J. Med. Chem. 55, 8350-8363
36. Chefer, V. I. and Shippenberg, T. S. (2009) Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice Neuropsychopharmacology 34, 887-898
37. Shippenberg, T. S., Chefer, V. I., and Thompson, A. C. (2009) Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine Biol. Psychiatry 65, 169-174
38. Su, Y. F., McNutt, R. W., and Chang, K. J. (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception J. Pharmacol. Exp. Ther. 287, 815-823
39. Foxx-Orenstein, A. E., Jin, J. G., and Grider, J. R. (1998) 5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion Am. J. Physiol. 275, G979-983
40. Koch, T. and Hollt, V. (2008) Role of receptor internalization in opioid tolerance and dependence Pharmacol. Ther. 117, 199-206
41. Cahill, C. M., Morinville, A., Lee, M. C., Vincent, J. P., Collier, B., and Beaudet, A. (2001) Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception J. Neurosci. 21, 7598-7607
42. Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000) Heterodimerization of mu and delta opioid receptors: A role in opiate synergy J. Neurosci. 20, RC110
43. Raehal, K. M. and Bohn, L. M. (2005) Mu opioid receptor regulation and opiate responsiveness AAPS J. 7, E587-591
44. Zhang, J., Ferguson, S. S., Barak, L. S., Bodduluri, S. R., Laporte, S. A., Law, P. Y., and Caron, M. G. (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness Proc. Natl. Acad. Sci. U.S.A. 95, 7157-7162
45. Brooks, B. R., Brooks, C. L., 3rd, MacKerell, A. D., Jr., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, R. W., Post, C. B., Pu, J. Z., Schaefer, M., Tidor, B., Venable, R. M., Woodcock, H. L., Wu, X., Yang, W., York, D. M., and Karplus, M. (2009) CHARMM: the biomolecular simulation program J. Comput. Chem. 30, 1545-1614
46. MacKerell, A. D., Jr., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T. K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wirkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102, 3586-3616
47. MacKerell, A. D., Jr., Feig, M., and Brooks, C. L., 3rd. (2004) Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations J. Comput. Chem. 25, 1400-1415
48. Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., and MacKerell, A. D., Jr. (2010) CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 31, 671-690
49. Sugita, Y. and Okamoto, Y. (1999) Replica-exchange molecular dynamics method for protein folding Chem. Phys. Lett. 314, 141-151
50. Zhou, R., Berne, B. J., and Germain, R. (2001) The free energy landscape for beta hairpin folding in explicit water Proc. Natl. Acad. Sci. U.S.A. 98, 14931-14936
51. Shim, J. and MacKerell, A. D., Jr. (2011) Computational ligand-based rational design: Role of conformational sampling and force fields in model development MedChemComm 2, 356-370
52. Lowery, J. J., Raymond, T. J., Giuvelis, D., Bidlack, J. M., Polt, R., and Bilsky, E. J. (2011) In vivo characterization of MMP-2200, a mixed delta/mu opioid agonist, in mice J. Pharmacol. Exp. Ther. 336, 767-778
53. Heyman, J. S., Koslo, R. J., Mosberg, H. I., Tallarida, R. J., and Porreca, F. (1986) Estimation of the affinity of naloxone at supraspinal and spinal opioid receptors in vivo: studies with receptor selective agonists Life Sci. 39, 1795-1803
54. Horan, P., Taylor, J., Yamamura, H. I., and Porreca, F. (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test J. Pharmacol. Exp. Ther. 260, 1237-1243